retatrutide type 2 diabetes phase 2 trial 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending The most intensive medical obesity

Real-World Trends in GLP-1 Treatment Persistence and Prescribing for Weight Management

To date, liraglutide, and the more effective once-weekly semaglutide, have been approved in the US and Europe for the treatment of obesity, with unprecedented weight loss of up to 1520%

Rare but serious effectssuch as pancreatitis or thyroid-related issuesshould be discussed with your provider

12, Acta Pharmaceutica Sinica B

Mochi leans on one-on-one video visits with providers and dietitians

Its innovative triple-receptor mechanism has positioned Retatrutide as a significant focus in modern metabolic and peptide research applications